OTCMKTS:OMBP Omni Bio Pharmaceutical (OMBP) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free OMBP Stock Alerts $0.0010 0.00 (0.00%) (As of 08/18/2020) Add Compare Share Share Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.00▼$0.04VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Omni Bio Pharmaceutical alerts: Email Address Ad Weiss RatingsBig Tech is spending billions each month on Nvidia’s AI superprojectA small handful of Nvidia’s partners could see their own stocks surge upwards. They’re virtually unknown right now, but that won’t be the case much longer.Click here to find out who they are today. About Omni Bio PharmaceuticalOmni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.Read More OMBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMBP Stock News HeadlinesMarch 2, 2024 | morningstar.comZhejiang Wolwo Bio-Pharmaceutical Co Ltd Class ADecember 2, 2023 | investing.comShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)November 12, 2023 | morningstar.comShanxi Jinbo Bio pharmaceutical Co Ltd 832982October 6, 2023 | nasdaq.comOversold Conditions For BridgeBio Pharma (BBIO)August 24, 2023 | morningstar.comSinopep Allsino Bio Pharmaceutical Co Ltd Class AMay 16, 2023 | wsj.comShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.April 22, 2023 | marketwatch.com2023 Bio Pharma Logistics Market | Dynamic Report By 2030April 21, 2023 | morningstar.comShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Class HMarch 31, 2023 | marketwatch.comBio-pharma Market Key Players and Forecast till 2031March 29, 2023 | marketwatch.com2023 Bio Pharma Logistics Market Size, Growth | Global Industry Trends [2029]March 25, 2023 | thestreet.comMy Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare ConferenceMarch 22, 2023 | wsj.comZhejiang Wolwo Bio Pharmaceutical Co. Ltd.February 22, 2023 | morningstar.comZhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A 300357 Stock QuoteJanuary 27, 2023 | marketwatch.comBio Pharma Logistics Market [Latest Report ]2023 is Booming with Figures, Sales Volume, Financial Barriers and Outlook to 2027January 5, 2023 | forbes.comBioMarin PharmaceuticalOctober 7, 2022 | reuters.comZhejiang Wolwo Bio-Pharmaceutical Co LtdSeptember 22, 2022 | investing.comSinopep Allsino Bio Pharmaceutical Co Ltd (688076)July 8, 2022 | apnews.comSlingshot Biosciences, Inc. Partners with OLS – OMNI Life Science to Distribute Synthetic Cells Throughout Germany, Austria, Switzerland, and ItalySee More Headlines Receive OMBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omni Bio Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/12/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:OMBP CUSIPN/A CIK1389870 Webwww.omnibiopharma.com Phone970-237-5178FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Leland Shapiro M.D.Principal Investigator for Viral & Bacterial DisordersKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAVAX TechnologiesOTCMKTS:AVXTClarus TherapeuticsOTCMKTS:CRXTQCornwall ResourcesOTCMKTS:CORCEnzon PharmaceuticalsOTCMKTS:ENZNView All Competitors OMBP Stock Analysis - Frequently Asked Questions How have OMBP shares performed in 2024? Omni Bio Pharmaceutical's stock was trading at $0.0010 on January 1st, 2024. Since then, OMBP shares have increased by 0.0% and is now trading at $0.0010. View the best growth stocks for 2024 here. What other stocks do shareholders of Omni Bio Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omni Bio Pharmaceutical investors own include Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), 23895 (GKX.V) (GKX), Flexion Therapeutics (FLXN), Biocept (BIOC) and Acorda Therapeutics (ACOR). How do I buy shares of Omni Bio Pharmaceutical? Shares of OMBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OMBP) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredPotentially Pocket $767/Day with AIWhat if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omni Bio Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omni Bio Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.